Ran Nussbaum has bought stock on 8 days since May 2017
Director at LB Pharmaceuticals Inc, and 4 other companies
SEC CIK 0001609805 · Filings on SEC.gov ↗
Ran Nussbaum's record
3 months after each buy, from the first price a copier could get.
1 buy has 3 months of prices so far. A record shows here at 3.
Companies
Every filing
8 filings since May 2017, newest first
Lb Pharmaceuticals Inc
Director
Eloxx Pharmaceuticals, Inc.
Director
Keros Therapeutics, Inc.
Director and 10% owner
Arqule Inc
Director
Arqule Inc
Director
Eloxx Pharmaceuticals, Inc.
Director
Eloxx Pharmaceuticals, Inc.
Director
Kite Pharma, Inc.
Director
About Ran Nussbaum
Ran Nussbaum is a prominent life-sciences investor, aged 52, serving as Managing Partner and Co-Founder of Pontifax, a venture capital firm focused on pharmaceuticals, biotech, and health services with over $370 million under management and more than 65 portfolio companies globally( He currently holds the position of Director at LB Pharmaceuticals Inc (LBRX), where he owns approximately 1,823,362 shares valued at over $36 million, reflecting his recent insider trading activity(
Nussbaum's career highlights include prior directorships at numerous public companies such as Keros Therapeutics (2016–2025), ArQule (acquired by Merck), Kite Pharma (acquired by Gilead), Prevail Therapeutics (acquired by Eli Lilly), VBI Vaccines, UroGen Pharma, BioBlast, and Eloxx, showcasing his expertise in guiding firms through strategic exits and governance( Before co-founding Pontifax in 2004, he served as CEO of Biomedix, Chairman of NasVax Ltd., and partner at Israel's largest business intelligence firm, emphasizing hands-on strategic oversight in biotech(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.